Marsico Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Marsico Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-20,877	Closed	-$2.56M	–	102
2016 Q3	$2.56M	Hold	20,877	–	–	0.1%	80
2016 Q2	$2.44M	Sell	20,877 -15,835	-43%	-$2.25M	0.08%	80
2016 Q1	$5.11M	Sell	36,712 -2,305	-6%	-$338K	0.15%	55
2015 Q4	$7.44M	Sell	39,017 -56,554	-59%	-$9.88M	0.13%	60
2015 Q3	$14.9M	Buy	+95,571	New	+$17.4M	0.16%	68
2015 Q1	–	Sell	-139,264	Closed	-$25.8M	–	103
2014 Q4	$25.8M	Buy	139,264 +9,360	+7%	+$1.73M	0.21%	49
2014 Q3	$21.5M	Sell	129,904 -2,564	-2%	-$421K	0.17%	63
2014 Q2	$20.7M	Buy	132,468 +12,501	+10%	+$1.97M	0.15%	62
2014 Q1	$18.3M	Sell	119,967 -16,554	-12%	-$2.63M	0.13%	72
2013 Q4	$18.2M	Buy	+136,521	New	+$16.4M	0.13%	74

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Marsico Capital Management's ALXN Position: Q4 2016 in Review

Marsico Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 20,877 shares — an estimated $2.56M sold.

Marsico Capital Management first reported a position in ALXN in Q4 2013 and held it in 10 quarters. The position peaked at $25.8M in Q4 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

Marsico Capital Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Marsico Capital Management sold 20,877 Alexion Pharmaceuticals shares in Q4 2016, an estimated $2.56M.
Marsico Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 10 quarters.
Marsico Capital Management's Alexion Pharmaceuticals position peaked at $25.8M in Q4 2014.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Marsico Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.